Airway disease: The use of large animal models for drug discovery

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 5, 2011, Pages 525-532

  Van der Velden, Joanne ^a   Snibson, Kenneth J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Asthma; COPD; Large animal models; Pigs; Respiratory disease; Sheep; Small airways

Indexed keywords

ALLERGEN; AMILORIDE; ANTIASTHMATIC AGENT; APAFANT; BENZAMIL; CAMOSTAT; CYSTEINYL LEUKOTRIENE RECEPTOR ANTAGONIST; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 MONOCLONAL ANTIBODY; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; METHACHOLINE; MODIPAFANT; MONTELUKAST; N (1 HYDROXY 2 NAPHTHOYL)ARGINYLPROLINAMIDE; PEPTIDOLEUKOTRIENE; PLACEBO; PURINERGIC P2Y2 RECEPTOR AGONIST; PURINERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL; SALMETEROL; SODIUM CHANNEL BLOCKING AGENT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG;

AIRWAY; AIRWAY HYPERRESPONSIVENESS; ALLERGIC ASTHMA; ARTICLE; ASTHMA; ATTENUATION; BRONCHOSPASM; CANNULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; EOSINOPHIL; EOSINOPHILIA; FORCED OSCILLATION TECHNIQUE; HISTOPATHOLOGY; HUMAN; IMMUNOGENICITY; LOEFFLER PNEUMONIA; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG FUNCTION; LUNG LYMPH; LUNG MECHANICS; MUCOCILIARY CLEARANCE; NONHUMAN; OSCILLATION; PATHOPHYSIOLOGY; PERIPHERAL AIRWAY; PHARMACOLOGICAL PARAMETERS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; SHEEP; SINGLE DRUG DOSE; SWINE; TREATMENT INDICATION;

ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; RESPIRATORY TRACT DISEASES; SHEEP; SPECIES SPECIFICITY;

EID: 80052422360     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.02.001     Document Type: Article

References (70)

1. Hedlund L.W., Johnson G.A. Morphology of the small-animal lung using magnetic resonance microscopy. Proc Am Thorac Soc 2005, 2:481-483. 501-2.
2. Glaab T., Taube C., Braun A., Mitzner W. Invasive and noninvasive methods for studying pulmonary function in mice. Respir Res 2007, 8(63).
3. Bates J.H., Rincon M., Irvin C.G. Animal models of asthma. Am J Physiol Lung Cell Mol Physiol 2009, 297:L401-L410.
4. Scheerlinck J.P., Snibson K.J., Bowles V.M., Sutton P. Biomedical applications of sheep models: from asthma to vaccines. Trends Biotechnol 2008, 26:259-266.
5. Kirschvink N., Reinhold P. Use of alternative animals as asthma models. Curr Drug Targets 2008, 470-484.
6. Abraham W.M. Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther 2008, 21:743-754.
7. Koumoundouros E., Bischof R.J., Meeusen E.N., Mareels I.M., Snibson K.J. Chronic airway disease: deteriorating pulmonary function in sheep associated with repeated challenges of house dust mite. Exp Lung Res 2006, 32:321-330.
8. Snibson K.J., Bischof R.J., Slocombe R.F., Meeusen E.N. Airway remodeling and inflammation in sheep lungs after chronic airway challenge with house dust mite. Clin Exp Allergy 2005, 35:146-152.
9. Pillow J.J., Hall G.L., Willet K.E., Jobe A.H., Hantos Z., Sly P.D. Effects of gestation and antenatal steroid on airway and tissue mechanics in newborn lambs. Am J Respir Crit Care Med 2001, 163:1158-1163.
10. Kaminsky D.A., Irvin C.G., Gurka D.A., Feldsien D.C., Wagner E.M., Liu M.C., et al. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med 1995, 152:1784-1790.
11. Kleeberger S.R., Kolbe J., Adkinson N.F., Peters S.P., Spannhake E.W. Central role of cyclooxygenase in the response of canine peripheral airways to antigen. J Appl Physiol 1986, 61:1309-1315.
12. Tsai L.W., Hoffman A.M., Mazan M.R., Ingenito E.P. Bronchoscopic measurement of collateral ventilation in a sheep model of emphysema. Respiration 2007, 74:565-571.
13. Menkes H.A., Traystman R.J. Collateral ventilation. Am Rev Respir Dis 1977, 116:287-309.
14. Wills-Karp M. IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol 2001, 107:9-18.
15. Kasaian M.T., Donaldson D.D., Tchistiakova L., Marquette K., Tan X.Y., Ahmed A., et al. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol 2007, 36:368-376.
16. Vugmeyster Y., Szklut P., Tchistiakova L., Abraham W., Kasaian M., Xu X. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 2008, 8:477-483.
17. Gauvreau G.M., Boulet L.P., Cockcroft D.W., Fitzgerald J.M., Carlsten C., Davis B.E., et al. The effects of IL-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011.
18. Yen H.H., Wee J.L., Snibson K.J., Scheerlinck J.P. Thoracic duct cannulation without thoracotomy in sheep: a method for accessing efferent lymph from the lung. Vet Immunol Immunopathol 2008.
19. Abraham W.M. Tryptase: potential role in airway inflammation and remodeling. Am J Physiol Lung Cell Mol Physiol 2002, 282:L193-L196.
20. Clark J.M., Abraham W.M., Fishman C.E., Forteza R., Ahmed A., Cortes A., et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med 1995, 152:2076-2083.
21. Sylvin H., Dahlbáck M., Van Der Ploeg I., Alving K. The tryptase inhibitor APC-366 reduces the acute airway response to allergen in pigs sensitized to Ascaris suum. Clin Exp Allergy 2002, 32:967-971.
22. Krishna M.T., Chauhan A., Little L., Sampson K., Hawksworth R., Mant T., et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol 2001, 107:1039-1045.
23. Hallstrand T.S., Henderson W.R. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010, 10:60-66.
24. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001, 56(Suppl. 66):7-11.
25. Jones T.R., Labelle M., Belley M., Champion E., Charette L., Evans J., et al. Pharmocology of montelukast sodium (Singulair), a potent and selective leukotriene D4 antagonist. Can J Physiol Pharmacol 1995, 73:191-201.
26. Reiss T.F., Sorkness C.A., Stricker W., Botto A., Busse W.W., Kundu S., et al. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997, 52:45-48.
27. Ramsay C.F., Pearson D., Mildenhall S., Wilson A.M. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax 2011, 66:7-11.
28. Diamant Z., Grootendorst D.C., Veselic C., Timmers De S., Smet M., Leff, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999, 29:42-51.
29. Mauser P.J., Pitman A.M., Fernandez X., Foran S.K., Adams G.K., Kreutner W., et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995, 152:467-472.
30. Egan R.W., Athwahl D., Chou C.C., Chapman R.W., Emtage S., Jenh C.H., et al. Pulmonary biology of anti-interleukin 5 antibodies. Mem Inst Oswaldo Cruz 1997, 92(Suppl. 2):69-73.
31. Hart T.K., Cook R.M., Zia-Amirhosseini P., Minthorn E., Sellers T.S., Maleeff B.E., et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001, 108:250-257.
32. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
33. Bradding P., Green R.H. Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol 2010, 10:54-59.
34. Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008, 372:1107-1119.
35. Zosky G.R., Sly P.D. Animal models of asthma. Clin Exp Allergy 2007, 37:973-988.
36. Tomioka K., Garrido R., Ahmed A., Stevenson J.S., Abraham W.M. YM461, a PAF antagonist, blocks antigen-induced late airway responses and airway hyperresponsiveness in allergic sheep. Eur J Pharmacol 1989, 170:209-215.
37. Gomez F.P., Rodriguez-Roisin R. Platelet-activating factor antagonists: current status in asthma. BioDrugs 2000, 14:21-30.
38. Kasperska-Zajac A., Brzoza Z., Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Pat Inflamm Allergy Drug Discov 2008, 2:72-76.
39. Freitag A., Watson R.M., Matsos G., Eastwood C., O'Byrne P.M. Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. Thorax 1993, 48:594-598.
40. Kuitert L.M., Hui K.P., Uthayarkumar S., Burke W., Newland A.C., Uden S., et al. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. Am Rev Respir Dis 1993, 147:82-86.
41. Abraham W.M., Stevenson J.S., Garrido R. A possible role for PAF in allergen-induced late responses: modification by a selective antagonist. J Appl Physiol 1989, 66:2351-2357.
42. Kidney J.C., Ridge S.M., Chung K.F., Barnes P.J. Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1993, 147:215-217.
43. Spencer D.A., Evans J.M., Green S.E., Piper P.J., Costello J.F. Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man. Thorax 1991, 46:441-445.
44. Fox J.C., Fitzgerald M.F. The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPD. Curr Opin Pharmacol 2009, 9:231-242.
45. Vlahos R., Bozinovski S., Hamilton J.A., Anderson G.P. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol Ther 2006, 112:106-115.
46. Vlahos R., Bozinovski S., Gualano R.C., Ernst M., Anderson G.P. Modelling COPD in mice. Pulm Pharmacol Ther 2006, 19:12-17.
47. Wright J.L., Cosio M., Churg A. Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2008, 295:L1-L15.
48. Borthwick D.W., West J.D., Keighren M.A., Flockhart J.H., Innes B.A., Dorin J.R. Murine submucosal glands are clonally derived and show a cystic fibrosis gene-dependent distribution pattern. Am J Respir Cell Mol Biol 1999, 20:1181-1189.
49. Plopper C.G., Hyde D.M. The non-human primate as a model for studying COPD and asthma. Pulm Pharmacol Ther 2008, 21:755-766.
50. Calabrese C., Bocchino V., Vatrella A., Marzo C., Guarino C., Mascitti S., et al. Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Respir Med 2006, 100:1415-1422.
51. Avdalovic M.V., Putney L.F., Schelegle E.S., Miller L., Usachenko J.L., Tyler N.K., et al. Vascular remodeling is airway generation-specific in a primate model of chronic asthma. Am J Respir Crit Care Med 2006, 174:1069-1076.
52. Hernandez J.A., Anderson A.E., Holmes W.L., Foraker A.G. Pulmonary parenchymal defects in dogs following prolonged cigarette smoke exposure. Am Rev Respir Dis 1966, 93:78-83.
53. Collie D.D., McLean N., Sallenave J.M., Baker A., Blundell R., Milne E., et al. Local lung responses following endobronchial elastase and lipopolysaccharide instillation in sheep. Int J Chron Obstruct Pulmon Dis 2006, 1:189-199.
54. Messina M.S., O'Riordan T.G., Smaldone G.C. Changes in mucociliary clearance during acute exacerbations of asthma. Am Rev Respir Dis 1991, 143:993-997.
55. Smaldone G.C., Foster W.M., O'Riordan T.G., Messina M.S., Perry R.J., Langenback E.G. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest 1993, 103:1390-1396.
56. Sabater J.R., Lee T.A., Abraham W.M. Comparative effects of salmeterol, albuterol, and ipratropium on normal and impaired mucociliary function in sheep. Chest 2005, 128:3743-3749.
57. Yerxa B.R., Sabater J.R., Davis C.W., Stutts M.J., Lang-Furr M., Picher M., et al. Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther 2002, 302:871-880.
58. Pons G., Marchand M.C., d'Athis P., Sauvage E., Foucard C., Chaumet-Riffaud P., et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The amiloride-aflm collaborative study group. Pediatr Pulmonol 2000, 30:25-31.
59. Hirsh A.J., Sabater J.R., Zamurs A., Smith R.T., Paradiso A.M., Hopkins S., et al. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2004, 311:929-938.
60. Hirsh A.J., Zhang J., Zamurs A., Fleegle J., Thelin W.R., Caldwell R.A., et al. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy) phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008, 325:77-88.
61. Coote K., Atherton-Watson H.C., Sugar R., Young A., MacKenzie-Beevor A., Gosling M., et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther 2009, 329:764-774.
62. Strausbaugh S.D., Davis P.B. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med 2007, 28:279-288.
63. Snouwaert J.N., Brigman K.K., Latour A.M., Iraj E., Schwab U., Gilmour M.I., et al. A murine model of cystic fibrosis. Am J Respir Crit Care Med 1995, 151:S59-S64.
64. Guilbault C., Saeed Z., Downey G.P., Radzioch D. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 2007, 36:1-7.
65. Scholte B.J., Davidson D.J., Wilke M., De Jonge H.R. Animal models of cystic fibrosis. J Cyst Fibros 2004, 3(Suppl. 2):183-190.
66. Welsh M.J., Rogers C.S., Stoltz D.A., Meyerholz D.K., Prather R.S. Development of a porcine model of cystic fibrosis. Trans Am Clin Climatol Assoc 2009, 120:149-162.
67. Stoltz D.A., Meyerholz D.K., Pezzulo A.A., Ramachandran S., Rogan M.P., Davis G.J., et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2011, 2. 29ra31.
68. Elsik C.G., Tellam R.L., Worley K.C., Gibbs R.A., Muzny D.M., Weinstock G.M., et al. The genome sequence of taurine cattle: a window to ruminant biology and evolution. Science 2009, 324:522-528.
69. Kirkness E.F., Bafna V., Halpern A.L., Levy S., Remington K., Rusch D.B., et al. The dog genome: survey sequencing and comparative analysis. Science 2003, 301:1898-1903.
70. van den Blink B., Jansen H.M., Peppelenbosch M.P. Idiopathic pulmonary fibrosis: molecular mechanisms and possible therapeutic strategies. Arch Immunol Ther Exp (Warsz) 2000, 48:539-545.